MDxHealth SA (MDXH) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome everyone joining today's MDX Health Second Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star 1 on your telephone keypad. Please note this call is being recorded. and we are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to John Francis with LifeSci Advisors. Please go ahead. Before we begin, I would like to remind everyone that the company will make forward-looking statements during today's call. Whether in prepared remarks or during the Q&A session, these forward-looking statements are subject to inherent risks and uncertainties. These risks and uncertainties are detailed in the risk factor section of the company's filings with the Securities and Exchange Commission, specifically in the company's annual report on Form 20F. I'll now turn the call over to Michael McGarrity, Chief Executive Officer. Thanks, John. And thank you all for joining us for our second quarter of 2026 Earnings Conference Call. With me today is Ron Kalfas, Interim Chief Financial Officer. Q2 was a pivotal quarter for MDX Health. Following the unanticipated reimbursement developments related to our resolve test in April, our Q2 results reflect the strength of our core business, which was precisely what we committed to deliver with our sales force focused solely on this significant market opportunity. More specifically, We communicated that we expected sequential revenue acceleration from Q1 to Q2. We generated a 14% sequential revenue increase for $3.3 million, representing the largest quarter-over-quarter revenue acceleration in our ...